Navigation Links
Does Anti-TNF Therapy Control Ankylosis ?

Arthritis is a condition resulting from inflammation of joints. It causes swelling and pain resulting in limited movement.//

Spondylarthritis (SpA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and inflammatory bowel disease are all associated rheumatic diseases collectively known as "spondyloarthropathies". Aside from chronic inflammation, these conditions are all characterized by ankylosis, stiffness and fusion of bone in the spine and peripheral joints. Ankylosis is an incapacitating condition that ultimately results in loss of spinal mobility and function severely affecting a person's quality of life.

Currently, inhibition of tumor necrosis factor á (TNFá) is the most effective strategy for controlling the painful symptoms of SpA and slowing vertebral joint destruction. But does anti-TNF therapy do anything to reduce the incidence or severity of ankylosis?

To answer this critical question, a quartet of researchers led by Dr. Frank P. Luyten, Division of Rheumatology, University Hospitals, Leuven, Belgium, tested the effectiveness of etanercept, an established TNF receptor, on animal models of arthritis.

Their findings, highlighted in the February 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), cast doubts on the feasibility of preventing joint and spine ankylosis with anti-TNF strategies while shedding light on the process of SpA.

A sample of male mice with spontaneous arthritis were caged together and observed from the age of 10 weeks. From week 12 to week 25, the mice were treated twice weekly with etanercept, in a strength comparable to standard dosage for human patients, or a placebo. Mice were also scored twice weekly for signs of arthritis, including cartilage formation, bone formation, and joint ankylosis. The mice were killed at age 25 weeks, autopsied, and analyzed, through cell population staining, for the presence of TNFá.


'"/>




Page: 1 2

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Does Anti TNF Therapy Control Ankylosis

(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...i, Feb 13 Valentine Day is assuming a new importa...ion in booming with Almost half// its population b...India has shed off old inhibitions and embraced li... Western festival of Valentine's Day despite oppos...
...een found through an animal study that Aspartame c... that drinking four to five 20-ounce bottles of di... the //cause of cancers. The study would be publi...onmental Health Perspectives, an US government-run...
...tempting to learn a new task, taking short breaks ...sy, according to a new study conducted by Massachu...Foster and Matthew Wilson, working at the Massachu...idge, found that rats' brains 'replay' their exper...
...ia in the year 2005 planned to begin stem cell res...ers passing the Proposition 71. But the legal chal...als now say that it would take spring 2007 before ..., president of the California Institute for Regene...
Other Medicine News:Health News:Valentine Day Becoming Popular In India 2Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
(Date:7/22/2008)...Including Lantus(R) and Apidra(R) Resulted in Sign... Diabetes, Whatever the Algorithm ... /- Results from the "Adjust to,Targe...ithm to Carbohydrate,Counting for Adjustment of Me... the American Diabetes Association,s (ADA) medical...
(Date:7/22/2008)...nd Validated by Columbia University Medical Center...MicroRNA Technology, The Test Differentiates Squ...r (NSCLC), Classifying Squamous-Cell Carcinoma of ... Specificity of 90 Percent,This is the First CLIA ...ty as Biomarkers for Accurate Diagnosis o...
(Date:7/22/2008)...Suggests That Ekkyo,s New Approach of LASH (Laser ... Scar Healing Physiology, MARSEILLES, France, Jul...wave Technology) a photomedicine company, which de... scar prevention and reduction, announced today,th... Surgery and Medicine*,reporting the results of a ...
(Date:7/21/2008)... 21 /- The SEAS (Simvastatin and Ezet...he effects of intensive,cholesterol lowering with ...zetimibe (10 mg daily) in patients with aortic ste...lockage of the aortic valve in,the heart) is a rel...rn,populations. Left untreated, it can progress to...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Cardiogenesis Reports First Quarter 2008 Results 19431 1Cardiogenesis Reports First Quarter 2008 Results 19431 2Cardiogenesis Reports First Quarter 2008 Results 19431 3Cardiogenesis Reports First Quarter 2008 Results 19431 4Cardiogenesis Reports First Quarter 2008 Results 19431 5Cardiogenesis Reports First Quarter 2008 Results 19431 6Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 1Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 1Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 3AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 1AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 2
...RE)--Apr 16, 2007 - Antigenics Inc.,(NASDAQ: AGEN)...ata,from a Phase 1/2 investigator-sponsored trial ...cophage(R) (vitespen) in,recurrent, high-grade gli...ociation of Neurological Surgeons (AANS; abstract,...onducted at the,Brain Tumor Research Center at the...
...ctive Anti-VEGF Antibodies Inhibited Tumor Growth ...er Model -, , - Peregrine,s Antibodies that Select...Have Advantages over Non-Selective Approaches - , ...ly Human,Antibody Support , Advancing Peregrine,s ...ANGELES and TUSTIN, Calif., April 16, 2007,/PRNews...
Other Medicine Technology:Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 2Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 3Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5
...re Platinum XL Concentrator offers all the great f...elp lower lifecycle costs. Platinum XL features an... preventative maintenance is required by 40%! Plat... now a full 5 years with no hour limit on the comp...
Introducing the new Platinum 10 concentrator. The Platinum 10 delivers the reliability, performance and value advantage you have come to expect from the Platinum line of concentrators and provides an
...ifeStyle Portable Oxygen Concentrator is the most ...re. At less than 10 lbs (4.5 kg), this unit was de...highly active oxygen patient., ,Operating as ...s of both an oxygen concentrator and an oxygen con...
OCD-3000 pnuematic conserving regulator.
Medicine Products: